News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalix Biotherapeutics, Inc. (PLX) Signs $280 Million Brazilian Gaucher Deal


6/19/2013 7:35:13 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease treatment. The Israeli company said an arm of the Brazilian Ministry of Health has committed to buying at least $40 million of the drug annually during the seven-year agreement for Uplyso, which is marketed as Elelyso in the United States and Israel. During the agreement, Protalix will transfer the technology needed for the Brazilian government to build at its own expense a factory to make a sustainable supply of Uplyso. Protalix doesn't have to complete the final stage of its technology transfer until the government has made at least $280 million in Uplyso purchases.

Help employers find you! Check out all the jobs and post your resume.

Read at BusinessWeek
Read at HA'ARETZ
Read at Globes Online
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES